This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Compared to Estimates, Beauty Health (SKIN) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Beauty Health (SKIN) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ModivCare (MODV) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of -103.70% and 0.81%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's What Key Metrics Tell Us About Beauty Health (SKIN) Q1 Earnings
by Zacks Equity Research
The headline numbers for Beauty Health (SKIN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
The Beauty Health Company (SKIN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Beauty Health (SKIN) delivered earnings and revenue surprises of 28.57% and 1.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of -2.52% and 3%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Compared to Estimates, The Beauty Health Company (SKIN) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for The Beauty Health Company (SKIN) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
LifeMD, Inc. (LFMD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
LifeMD, Inc. (LFMD) delivered earnings and revenue surprises of 14.29% and 10.36%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Doximity (DOCS) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 20.83% and 6.14%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Cencora (COR) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cencora (COR) delivered earnings and revenue surprises of 14.69% and 5%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
The Beauty Health Company (SKIN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for The Beauty Health Company (SKIN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of 11.54% and 0.83%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Does The Beauty Health Company (SKIN) Have the Potential to Rally 122.94% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for The Beauty Health Company (SKIN) points to a 122.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Implied Volatility Surging for Beauty Health (SKIN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Beauty Health (SKIN) stock based on the movements in the options market lately.
The Beauty Health Company (SKIN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
The Beauty Health Company (SKIN) delivered earnings and revenue surprises of 40% and 0.91%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Organon (OGN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Organon (OGN) delivered earnings and revenue surprises of 35.05% and 3.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Surgery Partners (SGRY) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of 300% and 0.05%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Beauty Health (SKIN) Stock Options
by Zacks Equity Research
Implied Volatility Surging for Beauty Health (SKIN) Stock OptionsInvestors need to pay close attention to Beauty Health (SKIN) stock based on the movements in the options market lately.
The Beauty Health Company (SKIN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
The Beauty Health Company (SKIN) delivered earnings and revenue surprises of -100% and 3.90%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
The Beauty Health Company (SKIN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
The Beauty Health Company (SKIN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Beauty Health (SKIN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Beauty Health (SKIN) stock based on the movements in the options market lately.
The Beauty Health Company (SKIN) Q4 Earnings Meet Estimates
by Zacks Equity Research
The Beauty Health Company (SKIN) delivered earnings and revenue surprises of 0% and 3.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Doximity (DOCS) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 29.41% and 3.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Beauty Health (SKIN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Beauty Health (SKIN) stock based on the movements in the options market lately.
Elevance Health (ELV) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 6.06% and 1.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
The Beauty Health Company (SKIN) Stock Jumps 11.4%: Will It Continue to Soar?
by Zacks Equity Research
The Beauty Health Company (SKIN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.